Issuance of Stock Acquisition Rights to Directors and Executive Officers
First written in FY2018-Q1. 12 of 14 entries say "Advanced", first in FY2018. Latest entry: FY2026-H1.
- FY2026-H1AdvancedAnnual report
「Resolution date: 28 April 2025; categories and number of grantees: 5 Company directors (excluding outside directors) and 14 Company executive officers and others; number of stock acquisition rights (rights)*: 629.」
For the stock acquisition rights approved on 28 April 2025, 629 rights for 62,900 underlying shares were issued to 5 directors and 14 executive officers and others. - FY2025-H1AdvancedAnnual report
「* The details as of the issuance of the stock acquisition right certificates on 13 May 2024 are presented.」
For the Series 10 stock acquisition rights approved on 26 April 2024, the disclosure stated that, as of issuance on 13 May 2024, there were 463 rights for 9,260 underlying shares, granted to 5 directors and 12 executive officers and others. - FY2024AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 26 April 2024: categories and number of grantees: 5 Company directors (excluding outside directors) and 12 Company executive officers and others; number of stock acquisition rights (rights): 463.」
The issuance of 463 Series 10 stock acquisition rights for 9,260 underlying shares to 5 directors and 12 executive officers and others was approved on 26 April 2024. - FY2024-Q1AdvancedAnnual report
「The details as of the issuance of the stock acquisition right certificates on 15 May 2023 are presented.」
For the Series 9 stock acquisition rights approved on 28 April 2023, the disclosure stated that 584 rights for 11,680 underlying shares were issued on 15 May 2023. - FY2023AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 28 April 2023: categories and number of grantees: 6 Company directors (excluding outside directors) and 12 Company executive officers; number of stock acquisition rights (rights): 584.」
The issuance of 584 Series 9 stock acquisition rights for 11,680 underlying shares to 6 directors and 12 executive officers was approved on 28 April 2023. - FY2023-Q1RestatedAnnual report
「Resolution date: 28 April 2022; categories and number of grantees: 6 Company directors (excluding outside directors) and 12 Company executive officers; number of stock acquisition rights (rights)*: 724.」
The disclosure of the 724 Series 8 stock acquisition rights granted to 6 directors and 12 executive officers under the resolution of 28 April 2022 continued. - FY2022AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 28 April 2022: categories and number of grantees: 6 Company directors (excluding outside directors) and 12 Company executive officers; number of stock acquisition rights (rights): 724.」
The issuance of 724 Series 8 stock acquisition rights for 14,480 underlying shares, to be granted to 6 directors and 12 executive officers, was approved. - FY2021AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 28 April 2021: categories and number of grantees: 6 Company directors (excluding outside directors) and 10 Company executive officers; number of stock acquisition rights (rights): 394.」
In addition to the issuance details for the Series 6 stock acquisition rights, the disclosure stated that, as of the filing date, 605 Series 7 stock acquisition rights for 12,100 underlying shares had been approved. - FY2021-Q1AdvancedAnnual report
「The details as of the issuance of the stock acquisition right certificates on 15 May 2020 are presented.」
For the Series 6 stock acquisition rights approved on 30 April 2020, the details as of issuance on 15 May 2020 were disclosed: 394 rights for 7,880 underlying shares, granted to 6 directors and 10 executive officers. - FY2020AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 30 April 2020: categories and number of grantees: 6 Company directors (excluding outside directors) and 10 Company executive officers; number of stock acquisition rights (rights): 394.」
The disclosure stated that 394 Series 6 stock acquisition rights for 7,880 underlying shares would be issued to 6 directors and 10 executive officers. - FY2020-Q1AdvancedAnnual report
「The details as of the issuance of the stock acquisition right certificates on 13 May 2019 are presented.」
For the Series 5 stock acquisition rights approved on 26 April 2019, the disclosure stated that, as of issuance on 13 May 2019, there were 421 rights for 8,420 underlying shares, granted to directors, executive officers, executive advisers and employees. - FY2019AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 26 April 2019: categories and number of grantees: 6 Company directors (excluding outside directors), 9 Company executive officers, 1 Company executive adviser, and 1 Company employee; number of stock acquisition rights (rights): 421.」
The disclosure stated that 421 Series 5 stock acquisition rights for 8,420 underlying shares would be allocated to directors, executive officers, executive advisers and employees. - FY2018AdvancedAnnual report
「Resolved at the Board of Directors meeting held on 27 April 2018: Number of stock acquisition rights (rights): 358; class, details and number of shares underlying the stock acquisition rights (shares): common shares, 35,800.」
The issuance of 358 Series 4 stock acquisition rights for 35,800 underlying shares, to be granted to directors, executive officers and executive advisers, was approved. - FY2018-Q1First statedAnnual report
「During the first quarter, the Company issued stock acquisition rights. The details of these stock acquisition rights are as follows.」
Issued 427 stock acquisition rights for 42,700 underlying shares. The exercise period runs from 16 May 2019 to 15 May 2034, and the payment required upon exercise is ¥1 per share. The exercise conditions specify that the holder must hold a position such as director or executive officer of the Company or a group company.